Literature Scan
(morphine = 7%; methadone = 6%;
fentanyl patch = 2%).
Patients who reported no pain
in the past six months appeared
to be younger than those who
reported acute pain only or any
chronic pain (median age = 27.3,
32.9, and 35.3 years, respectively;
p values not reported). Employ-
ment status did not appear to
affect the incidence of chronic
drugs (34% and 49%). Many
patients also relied on non-
pharmacologic strategies, includ-
ing ice (65% and 33%) and rest
(51% and 33%).
Hydrocodone-acetaminophen
was the most common opioid used
for both acute and chronic pain
(27% and 30%, respectively); other
long-acting opioids were infrequent-
ly used, specifically for chronic pain
pain, with similar rates of chronic
pain between unemployed and
employed participants (31%
and 33%, respectively; p value
not reported), but did affect the
incidence of acute and chronic
pain (39% vs. 28%; p value not
reported).
In addition, patients with both
acute and chronic pain were more
often married or with a long-term
partner and more often lived with
others. Compared with those re-
porting no pain, only acute pain,
or only chronic pain, patients
with both acute and chronic pain
also were more likely to have (p
values not reported):
• depression (30% vs. 0-15%)
• obesity (35% vs. 20-29%)
T:7”
• lower health-related quality-of-
life scores (mean EQ-5D visual
analog scale = 69 vs. 83-86)
may cause dizziness or confusional state without
adequate medical advice [see Warnings and
Precautions (5.7)].
Neuropathy
Inform patients of the risk of neuropathy and to
report the signs and symptoms associated with
these events to their healthcare provider for further
evaluation [see Warnings and Precautions (5.8)].
Second Primary Malignancies
Inform the patient that the potential risk of developing
acute myelogenous leukemia during treatment with
POMALYST is unknown [see Warnings and
Precautions (5.9)].
Tumor Lysis Syndrome
Inform patients of the potential risk of tumor lysis
syndrome and to report any signs and symptoms
associated with this event to their healthcare
provider for evaluation [see Warnings and
Precautions (5.10)].
Smoking Tobacco
Advise patients that smoking tobacco may reduce
the efficacy of POMALYST.
Dosing Instructions
Inform patients on how to take POMALYST [see
Dosage and Administration (2.1)]
• POMALYST should be taken once daily at about
the same time each day.
• Patients on hemodialysis should take POMALYST
following hemodialysis, on hemodialysis days.
• POMALYST may be taken with or without food.
• The capsules should not be opened, broken, or
chewed. POMALYST sho